glp 1 is tirzepatide Beyond glycemia: Comparing to GLP-1 analogues | Reviews in Endocrine and Metabolic Disorders Tirzepatide (GLP-1 / GIP)

Whatever the reason, remaining at 2.5 or 5 mg when your body has adapted to that dose means the medication is no longer providing sufficient appetite suppression

Waiting 4 weeks between dose escalations allows the body to adapt to increasing drug exposure and minimizes gastrointestinal adverse effects, the most common reason for treatment discontinuation

The honest trade is in the structure: a 15 mg patient pays $112 more every month than a 2.5 mg patient, more than $1,300 of price drift over a year of titration

The Health Sciences Authority approved Mounjaro injection in March 2023 for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

The closing thoughts show the true benefits of using tirzepatide for a longer time